Processa Pharmaceuticals, Inc. Impairment of Long-Lived Assets to be Disposed of
Processa Pharmaceuticals, Inc. (PCSA) reported Impairment of Long-Lived Assets to be Disposed of of $186.07 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2017-09-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf · last filed 2017-09-25
- Processa Pharmaceuticals, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2015-12-31 was $131.51K.
- Processa Pharmaceuticals, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2015-09-30 was $54.56K.
- Processa Pharmaceuticals, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2015-06-30 was $1.52M.
- Processa Pharmaceuticals, Inc. impairment of long-lived assets to be disposed of for fiscal 2015 was $186.07K.
| Period end | Impairment of Long-Lived Assets to be Disposed of 3 month | Impairment of Long-Lived Assets to be Disposed of 3 month as first filed | Impairment of Long-Lived Assets to be Disposed of 6 month | Impairment of Long-Lived Assets to be Disposed of 9 month | Impairment of Long-Lived Assets to be Disposed of 9 month as first filed | Impairment of Long-Lived Assets to be Disposed of 12 month |
|---|---|---|---|---|---|---|
| 2015-12-31 | $131.51K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $186.07K derived: sum of 2 quarters · filed 2017-09-25 | $1.70M derived: sum of 3 quarters · filed 2017-09-25 | $186.07K 10-K · filed 2017-09-25 | ||
| 2015-09-30 | $54.56K 10-Q · filed 2017-09-08 | $85.00K 10-Q · filed 2015-12-01 | $1.57M derived: sum of 2 quarters · filed 2017-09-08 | $54.56K 10-Q · filed 2017-09-08 | $85.00K 10-Q · filed 2015-12-01 | |
| 2015-06-30 | $1.52M 10-Q · filed 2017-08-30 | $1.52M 10-Q · filed 2017-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |